Search
Close this search box.

Press Releases

Helsinn Group and BridgeBio Pharma’s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma

Helsinn Group and BridgeBio Pharma’s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma – Health Canada Issues Conditional Approval of TRUSELTIQ under Project Orbis (September 27th, 2021) LUGANO, Switzerland, and PALO ALTO, CA,

Read More